Cargando…
Brensocatib (an oral, reversible inhibitor of dipeptidyl peptidase-1) attenuates disease progression in two animal models of rheumatoid arthritis
Rheumatoid arthritis (RA) is a painful and incurable disease characterized by chronic joint inflammation and a progressive destruction of cartilage and bone. Although current treatments have improved clinical outcomes for some patients, the high relapse rates and sizeable proportion of non-responder...
Autores principales: | McDonald, Patrick P., Leifer, Franziska Graf, Basso, Jessica, Lasala, Dan, Li, Dedong, Chen, Kuan-Ju, Zhang, Jimin, Perkins, Walter R., Cipolla, David C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451067/ https://www.ncbi.nlm.nih.gov/pubmed/37638021 http://dx.doi.org/10.3389/fimmu.2023.1231047 |
Ejemplares similares
-
Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1, mitigates interferon-α-accelerated lupus nephritis in mice
por: Chen, Kuan-Ju, et al.
Publicado: (2023) -
Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial
por: Cipolla, David, et al.
Publicado: (2023) -
The pharmacokinetic profile of brensocatib and its effect on pharmacodynamic biomarkers including NE, PR3, and CatG in various rodent species
por: Basso, Jessica, et al.
Publicado: (2023) -
Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis
por: Chalmers, James D., et al.
Publicado: (2022) -
Safety, Tolerability, and Pharmacokinetic Evaluation of Single and Multiple Doses of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib in Healthy Japanese and White Adults
por: Usansky, Helen, et al.
Publicado: (2022)